Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan A Tobert

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Nature Reviews. Drug Discovery|June 20, 2003
Lovastatin and beyond: the history of the HMG-CoA reductase inhibitorsJonathan A Tobert
Endocrinology and Metabolism Clinics of North America|August 13, 2022
LDL Cholesterol-How Low Can We Go?Jonathan A Tobert
International Journal of Cardiology|May 1, 2018
Statins - Good drugs, not so good reputationJonathan A Tobert
European Heart Journal. Quality of Care & Clinical Outcomes|September 27, 2017
Now is good, earlier is betterJonathan A Tobert, David Preiss
Annals of Internal Medicine|April 5, 2016
Management of Dyslipidemia for Cardiovascular Disease Risk ReductionJonathan A Tobert, Connie B Newman
Journal of Clinical Lipidology|February 20, 2016
Comment on the article by Moriarty et alConnie B Newman, Jonathan A Tobert
Expert Opinion on Pharmacotherapy|December 2, 2004
Simvastatin: a reviewTerje R Pedersen, Jonathan A Tobert
The Journal of Clinical Endocrinology and Metabolism|December 5, 2022
Targeting PCSK9 With Antibodies and Gene Silencing to Reduce LDL CholesterolConnie B Newman, Jonathan A Tobert
Journal of Clinical Lipidology|September 1, 2016
The nocebo effect in the context of statin intoleranceJonathan A Tobert, Connie B Newman
JAMA|March 11, 2015
Statin intolerance: reconciling clinical trials and clinical experienceConnie B Newman, Jonathan A Tobert
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Nature Reviews. Drug Discovery|June 20, 2003
Lovastatin and beyond: the history of the HMG-CoA reductase inhibitorsJonathan A Tobert
Endocrinology and Metabolism Clinics of North America|August 13, 2022
LDL Cholesterol-How Low Can We Go?Jonathan A Tobert
International Journal of Cardiology|May 1, 2018
Statins - Good drugs, not so good reputationJonathan A Tobert
European Heart Journal. Quality of Care & Clinical Outcomes|September 27, 2017
Now is good, earlier is betterJonathan A Tobert, David Preiss
Annals of Internal Medicine|April 5, 2016
Management of Dyslipidemia for Cardiovascular Disease Risk ReductionJonathan A Tobert, Connie B Newman
Journal of Clinical Lipidology|February 20, 2016
Comment on the article by Moriarty et alConnie B Newman, Jonathan A Tobert
Expert Opinion on Pharmacotherapy|December 2, 2004
Simvastatin: a reviewTerje R Pedersen, Jonathan A Tobert
The Journal of Clinical Endocrinology and Metabolism|December 5, 2022
Targeting PCSK9 With Antibodies and Gene Silencing to Reduce LDL CholesterolConnie B Newman, Jonathan A Tobert
Journal of Clinical Lipidology|September 1, 2016
The nocebo effect in the context of statin intoleranceJonathan A Tobert, Connie B Newman
JAMA|March 11, 2015
Statin intolerance: reconciling clinical trials and clinical experienceConnie B Newman, Jonathan A Tobert
Pageof 2